The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses

M.C. Jones, Keith Nicol Stewart, D J PROPPER, G.R.D Catto, D A POWER

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antigen pre-treatment in animals undoubtedly prolongs graft survival. In man, however, routine pre-transplantation blood transfusions have recently become controversial, principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates. We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies. A total of 24 patients were recruited to the study; ten received cyclosporin with blood transfusions (BT) (group 1), 14 received BT alone (group 2). Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 (P < 0.05). Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 (P < 0.006) The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalNephrology Dialysis Transplantation
Volume6
Issue number2
Publication statusPublished - 1991

Keywords

  • CYCLOSPORINE
  • ALLOANTIBODIES
  • ANTIIDIOTYPIC ANTIBODIES
  • SENSITIZATION
  • RENAL-ALLOGRAFT RECIPIENTS
  • DONOR-SPECIFIC TRANSFUSION
  • TRANSPLANT RECIPIENTS
  • BROAD SENSITIZATION
  • KIDNEY-TRANSPLANTS
  • GRAFT-SURVIVAL
  • CROSSMATCH
  • RELEVANCE
  • ASSAY

Cite this

Jones, M. C., Stewart, K. N., PROPPER, D. J., Catto, G. R. D., & POWER, D. A. (1991). The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses. Nephrology Dialysis Transplantation, 6(2), 125-130.

The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses. / Jones, M.C.; Stewart, Keith Nicol; PROPPER, D J ; Catto, G.R.D ; POWER, D A .

In: Nephrology Dialysis Transplantation, Vol. 6, No. 2, 1991, p. 125-130.

Research output: Contribution to journalArticle

Jones, MC, Stewart, KN, PROPPER, DJ, Catto, GRD & POWER, DA 1991, 'The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses', Nephrology Dialysis Transplantation, vol. 6, no. 2, pp. 125-130.
Jones, M.C. ; Stewart, Keith Nicol ; PROPPER, D J ; Catto, G.R.D ; POWER, D A . / The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses. In: Nephrology Dialysis Transplantation. 1991 ; Vol. 6, No. 2. pp. 125-130.
@article{831ca9c63f7c4408b1a0b69759775dc0,
title = "The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses",
abstract = "Antigen pre-treatment in animals undoubtedly prolongs graft survival. In man, however, routine pre-transplantation blood transfusions have recently become controversial, principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates. We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies. A total of 24 patients were recruited to the study; ten received cyclosporin with blood transfusions (BT) (group 1), 14 received BT alone (group 2). Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 (P < 0.05). Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 (P < 0.006) The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear.",
keywords = "CYCLOSPORINE, ALLOANTIBODIES, ANTIIDIOTYPIC ANTIBODIES, SENSITIZATION, RENAL-ALLOGRAFT RECIPIENTS, DONOR-SPECIFIC TRANSFUSION, TRANSPLANT RECIPIENTS, BROAD SENSITIZATION, KIDNEY-TRANSPLANTS, GRAFT-SURVIVAL, CROSSMATCH, RELEVANCE, ASSAY",
author = "M.C. Jones and Stewart, {Keith Nicol} and PROPPER, {D J} and G.R.D Catto and POWER, {D A}",
year = "1991",
language = "English",
volume = "6",
pages = "125--130",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "OXFORD UNIV PRESS",
number = "2",

}

TY - JOUR

T1 - The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses

AU - Jones, M.C.

AU - Stewart, Keith Nicol

AU - PROPPER, D J

AU - Catto, G.R.D

AU - POWER, D A

PY - 1991

Y1 - 1991

N2 - Antigen pre-treatment in animals undoubtedly prolongs graft survival. In man, however, routine pre-transplantation blood transfusions have recently become controversial, principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates. We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies. A total of 24 patients were recruited to the study; ten received cyclosporin with blood transfusions (BT) (group 1), 14 received BT alone (group 2). Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 (P < 0.05). Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 (P < 0.006) The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear.

AB - Antigen pre-treatment in animals undoubtedly prolongs graft survival. In man, however, routine pre-transplantation blood transfusions have recently become controversial, principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates. We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies. A total of 24 patients were recruited to the study; ten received cyclosporin with blood transfusions (BT) (group 1), 14 received BT alone (group 2). Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 (P < 0.05). Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 (P < 0.006) The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear.

KW - CYCLOSPORINE

KW - ALLOANTIBODIES

KW - ANTIIDIOTYPIC ANTIBODIES

KW - SENSITIZATION

KW - RENAL-ALLOGRAFT RECIPIENTS

KW - DONOR-SPECIFIC TRANSFUSION

KW - TRANSPLANT RECIPIENTS

KW - BROAD SENSITIZATION

KW - KIDNEY-TRANSPLANTS

KW - GRAFT-SURVIVAL

KW - CROSSMATCH

KW - RELEVANCE

KW - ASSAY

M3 - Article

VL - 6

SP - 125

EP - 130

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 2

ER -